缺血性心脏病的免疫调节治疗
缺血性心脏病是全球主要死因,心肌梗死后恢复心脏功能的干预措施匮乏。累积证据表明缺血微环境中组织免疫受损加重心功能障碍并促进心力衰竭进展。近期研究提出免疫治疗可利用免疫和基质细胞重校准免疫微环境,本文重点介绍三种新兴免疫调节策略。
要点
- 靶向血管内皮细胞可重连组织免疫。
- 重编程髓系细胞以增强其修复功能。
- 利用过继性T细胞疗法改善纤维化。
核心结论
- 免疫调节治疗有望为缺血性心脏病治疗提供新机会。
研究设计与样本
- 本文为Primer综述,未报告系统检索范围与样本量。
主要发现
- 缺血微环境中组织免疫受损加重心功能障碍,促进进行性心力衰竭。
- 靶向血管内皮细胞以重连组织免疫是新兴免疫调节策略之一。
- 重编程髓系细胞以增强其修复功能是新兴免疫调节策略之一。
- 利用过继性T细胞疗法改善纤维化是新兴免疫调节策略之一。
临床怎么用
- 免疫调节治疗可作为心肌梗死后恢复心脏功能的潜在治疗方向。
局限性
- 原文未报告具体研究设计、样本量及定量数据。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Ischemic heart disease is a leading cause of death worldwide, manifested clinically as myocardial infarction (and ischemic cardiomyopathy. Presently, there exists a notable scarcity of efficient interventions to restore cardiac function after myocardial infarction. Cumulative evidence suggests that impaired tissue immunity within the ischemic microenvironment aggravates cardiac dysfunction, contributing to progressive heart failure. Recent research breakthroughs propose immunotherapy as a potential approach by leveraging immune and stroma cells to recalibrate the immune microenvironment, holding significant promise for the treatment of ischemic heart disease. In this Primer, we highlight three emerging strategies for immunomodulatory therapy in managing ischemic cardiomyopathy: targeting vascular endothelial cells to rewire tissue immunity, reprogramming myeloid cells to bolster their reparative function, and utilizing adoptive T cell therapy to ameliorate fibrosis. We anticipate that immunomodulatory therapy will offer exciting opportunities for ischemic heart disease treatment.
引用
- Zhao X, Williamson T, Gong Y, et al. Immunomodulatory Therapy for Ischemic Heart Disease. Circulation. 2024. PMID: 39325497. doi:10.1161/CIRCULATIONAHA.124.070368
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。